Innoviva Stock Crosses 200-Day Moving Average
Shares of Innoviva, Inc. (NASDAQ:INVA) have crossed above their 200-day moving average, indicating a potential bullish trend. This surge is attributed to positive analyst sentiment and the company's stable, royalty-focused business model in the biotech sector. Analysts maintain a 'Moderate Buy' rating with an average price target of $34.80, suggesting further upside potential for the stock.
INVA Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for INVA, detailing past quarterly results and future estimates. It highlights that analysts project Q1 2026 revenue of $100.31M and an EPS of $0.39, with recent estimates showing no change. The report also examines how INVA's stock price typically reacts to earnings announcements, noting a 0.99% change 10 days before and a 3.2% change 10 days after, suggesting potential buying opportunities based on long-term fundamentals.
Innoviva Inc (HVE.SG) Stock Price, News, Quote & History
This page provides comprehensive financial information for Innoviva Inc (HVE.SG), including its current stock price, recent news, quotes, and historical data. As of April 2, 2026, the stock was trading at 19.80 EUR, down 1.98%. The page also details performance metrics compared to the S&P 500, showing Innoviva's YTD return at +20.73% and 1-year return at +20.73%.
Innoviva, Inc. (INVA) stock price, news, quote and history
This article provides a comprehensive overview of Innoviva, Inc. (INVA), a biopharmaceutical company, including its stock price, historical data, and financial performance. It details the company's royalty portfolio of medicines, development pipeline, key financial metrics like market cap and P/E ratio, and analyst insights. The report also lists comparable companies in the biotechnology sector.
INVA Stock Price, Quote & Chart | INNOVIVA INC (NASDAQ:INVA)
This article provides a detailed overview of INNOVIVA INC (NASDAQ:INVA) stock, including its current price, performance metrics, and key statistics. It also highlights ChartMill's technical and fundamental ratings, recent earnings reports, analyst forecasts, and company profile. The stock is noted for its strong financial health, profitability, and inclusion in several "value" stock screens.
INVA PE Ratio & Valuation, Is INVA Overvalued
Innoviva Inc (INVA) is currently considered undervalued, with a forward PE ratio of 7.57 compared to its five-year average of 11.86. Its fair price is estimated between $35.41 and $65.32, significantly above its current price of $23.41, indicating it is undervalued by 33.89%. The company also shows a P/B ratio of 1.48 and a Forward FCF yield of 11.25%, with robust revenue growth contributing to a sustainable premium.
Working capital per share of Innoviva, Inc. – BX:HVE
This article provides financial information for Innoviva, Inc. (BX:HVE) on TradingView, specifically focusing on its working capital per share. It mentions the company's market status on BX Swiss and highlights available financial data.
Price-Driven Insight from (INVA) for Rule-Based Strategy
This article provides a price-driven insight for Innoviva Inc. (NASDAQ: INVA) for rule-based trading strategies, highlighting a near-term strong sentiment transitioning to mid-term neutrality and long-term positive bias. It presents specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and risk-reward ratios. The analysis emphasizes AI-generated signals for entry and exit points, support, and resistance levels.
Book value per share of Innoviva, Inc. – BX:HVE
This article provides financial information for Innoviva, Inc. (BX:HVE), specifically focusing on its book value per share. It details the period, value, and percentage change of this metric, indicating that the market is currently closed.
Net current asset value per share of Innoviva, Inc. – BX:HVE
This page from TradingView provides financial information for Innoviva, Inc. (HVE BX Swiss), specifically focusing on its net current asset value per share. The content displays a table with "Period," "Value," "Change," and "Change %" for this metric.
INVA Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Innoviva Inc.'s (INVA) financial performance, focusing on its revenue breakdown, profitability margins, and a comparison with competitors HRMY and VCEL. INVA demonstrates strong profitability with a gross margin of 66.02%, an operating margin of 34.02%, and a net margin of 143.22%, alongside a 29.09% Return on Equity. The company, with a market capitalization of $1.68B, holds a leading position in its sector despite slightly lower gross margins compared to some rivals.
Innoviva (INVA) files 10-K/A adding Armata audited financials and new officer certifications
Innoviva, Inc. (INVA) filed an Amendment No. 1 to its 2025 Annual Report (Form 10-K/A) to incorporate audited financial statements for Armata Pharmaceuticals, Inc. and new certifications from its principal executive and financial officers. This amendment was made to comply with SEC Rule 3-09 of Regulation S-X, which requires separate financial reporting for significant equity investees. The filing explicitly states that all other disclosures in the original annual report remain unchanged, including Innoviva's previously reported financial results.
Vanguard discloses 0% Innoviva holding (NASDAQ: INVA)
Vanguard has filed an Amendment No. 10 to its Schedule 13G/A, reporting 0% beneficial ownership of Innoviva Inc. (NASDAQ: INVA) common stock. This change follows an internal realignment on January 12, 2026, where Vanguard and certain subsidiaries will now report beneficial ownership separately. The filing clarifies that Vanguard no longer holds, or is deemed to hold, beneficial ownership over these securities.
INNOVIVA PB Ratio: 1.44 — 30% Below Median
Innoviva Inc (INVA) has a Price-to-Book (PB) Ratio of 1.44 as of March 27, 2026, which is 30% below its 10-year median of 2.07. GuruFocus rates INVA with a GF Score of 88/100 and a GF Value of $19.31, indicating it is modestly overvalued, and notes 5 warning signs for investors. Despite its lower-than-median PB Ratio and strong industry ranking within biotechnology, GuruFocus's overall analysis suggests the stock is currently overvalued compared to its estimated fair value.
Innoviva, Inc. (NASDAQ:INVA) Receives Consensus Rating of "Moderate Buy" from Analysts
Innoviva, Inc. (NASDAQ:INVA) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $34.80. The company reported strong quarterly earnings, exceeding expectations with $1.94 EPS and $114.61 million in revenue. Institutional investors hold a significant 99.12% stake, with major funds increasing their positions.
Oliver Luxxe Assets LLC Invests $1.69 Million in Innoviva
Oliver Luxxe Assets LLC has acquired a new stake of 84,671 shares in Innoviva, Inc. (NASDAQ:INVA) valued at approximately $1.69 million during the fourth quarter of 2025. This investment signifies continued institutional confidence in the biotechnology company, which focuses on respiratory therapies. Other institutional investors like Creative Planning and Oregon Public Employees Retirement Fund also adjusted their holdings in Innoviva during the same period.
Innoviva (NASDAQ:INVA) Stock Crosses Above Two Hundred Day Moving Average - Here's Why
Innoviva (NASDAQ:INVA) stock has crossed above its 200-day moving average, trading at $22.09 against a $20.28 average after reaching a high of $22.37. Analysts maintain a "Moderate Buy" consensus with an average price target of $34.80, following strong Q4 earnings where the company significantly beat EPS and revenue expectations. Institutional investors have also increased their positions, indicating strong confidence in the biotechnology company.
(INVA) Price Dynamics and Execution-Aware Positioning
The article provides an AI-driven analysis of Innoviva Inc. (NASDAQ: INVA) stock, highlighting a divergent sentiment across various time horizons and suggesting choppy market conditions. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes a significant 35.0:1 risk-reward setup targeting a 9.8% gain with minimal risk, based on multi-timeframe signal analysis.
Assessing Innoviva (INVA) Valuation After Strong Earnings Growth And Portfolio Expansion
Innoviva (INVA) reported strong Q4 and full-year 2025 results, including increased revenue, a sharp net income jump, new product approvals, and a share repurchase plan, driving an 8.34% share price increase over the last month. Despite a low P/E ratio of 6.2x compared to the industry average, a Discounted Cash Flow model suggests a significant undervaluation with an estimated future cash flow value of $54.47 per share against its current price of $22.73. The article advises investors to consider both the P/E ratio and DCF model, including associated risks and rewards, as the company transitions from a royalty-focused model to hospital and critical care markets.
How Investors May Respond To Innoviva (INVA) Surging EPS From Continuing Operations
Innoviva Inc. reported a significant increase in Q4 2025 and full-year 2025 revenue and net income, with a sharp rise in EPS from continuing operations. This surge in earnings may reset short-term expectations for the company, although investors should consider that not all recent profits may be repeatable due to a large non-recurring gain. Despite a strong share price run, some fair value estimates suggest the stock could still be undervalued, creating a tension between its recent performance and future profit forecasts.
How Investors May Respond To Innoviva (INVA) Surging EPS From Continuing Operations
Innoviva, Inc. reported significantly higher fourth-quarter and full-year 2025 revenues and net income, with a sharp increase in EPS from continuing operations, attributed partly to a large non-recurring gain. This earnings strength raises questions about its repeatability and influences Innoviva's investment narrative, with its share price rising but still potentially undervalued. Investors should consider the sustainability of these earnings and the tension between strong past performance and future profit forecasts.
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report
Innoviva Specialty Therapeutics received a strong performance rating of 80% in the Access to Medicine Foundation's 2026 Antimicrobial Resistance (AMR) Benchmark Report, the highest in the SME category. This recognition highlights the company's commitment to developing innovative therapies for serious infections, including its FDA-approved NUZOLVENCE® for uncomplicated urogenital gonorrhea. The report particularly noted their partnership with GARDP and their focus on R&D for priority pathogens.
Quantbot Technologies LP Lowers Stake in Innoviva, Inc. $INVA
Quantbot Technologies LP significantly reduced its holding in Innoviva, Inc. by 67.4% during the third quarter, ending with 41,916 shares valued at approximately $765,000. Despite this reduction, Innoviva reported strong financial results, surpassing earnings estimates with $1.94 EPS and $114.6 million in revenue, boasting a 65.9% net margin. Analysts currently maintain a "Moderate Buy" rating for Innoviva, with an average target price of $34.80.
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report
Innoviva Specialty Therapeutics received a strong performance rating of 80% in the Access to Medicine Foundation's 2026 Antimicrobial Resistance (AMR) Benchmark Report, the highest in the SME category. This recognition highlights their commitment to developing new therapies for life-threatening infections, particularly with their FDA-approved NUZOLVENCE® for gonorrhea, which meets three of four WHO innovation criteria. The report acknowledges the company's R&D efforts and integration of access and stewardship in their development plans.
(INVA) as a Liquidity Pulse for Institutional Tactics
The article analyzes Innoviva Inc. (NASDAQ: INVA) as a liquidity pulse for institutional tactics, noting a weak near-term sentiment but strong long-term outlook. It identifies an exceptional 35.7:1 risk-reward setup, targeting a 10.1% gain against 0.3% risk. The analysis provides three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
American Century Companies Inc. Boosts Stake in Innoviva, Inc.
American Century Companies Inc. significantly increased its stake in Innoviva, Inc. by 13.8% in the third quarter of the previous year, now owning 2,351,006 shares. This investment highlights continued institutional interest in Innoviva, a biotech company focused on respiratory therapies and a royalty-based business model. The transaction suggests American Century sees long-term value and growth potential in the company.
American Century Companies Inc. Buys 284,253 Shares of Innoviva, Inc. $INVA
American Century Companies Inc. increased its stake in Innoviva, Inc. by 13.8% in the third quarter, acquiring an additional 284,253 shares and bringing its total holdings to 2,351,006 shares valued at $42.9 million. Innoviva recently reported strong quarterly earnings, beating analyst estimates with an EPS of $1.94 and revenue of $114.6 million. Analysts generally have a "Moderate Buy" rating for Innoviva, with an average price target of $34.80.
Analysts Offer Predictions for Innoviva FY2027 Earnings
HC Wainwright analysts forecast Innoviva's FY2027 earnings per share to be $2.50, reiterating a "Buy" rating and a $46 price target. While recent Q4 results outperformed expectations, analysts have adjusted near-term FY2026 estimates downwards, potentially causing short-term pressure despite positive long-term outlooks. Innoviva, a royalty-focused life sciences company, continues to be largely owned by institutional investors.
HC Wainwright Has Bearish Forecast for Innoviva Q1 Earnings
HC Wainwright has revised its Q1 2026 EPS estimate for Innoviva (NASDAQ:INVA) downward to $0.42 from $0.45, and also lowered its FY2026 forecast to $1.96. Despite these reductions, the firm maintains a "Buy" rating and a $46 price target, indicating significant potential upside given Innoviva's current trading price around $22.30 and strong recent earnings performance. The biotechnology company, which focuses on royalty interests in respiratory therapies, is largely owned by institutional investors, and carries a "Moderate Buy" consensus rating among analysts.
Assessing Innoviva (INVA) Valuation After Strong Earnings Growth And Portfolio Expansion
Innoviva (INVA) has reported strong Q4 and full-year 2025 results, with increased revenue, a significant jump in net income, new product approvals, and a share repurchase plan, signaling a successful transition to hospital and critical care markets. The company's stock shows momentum, trading at a low P/E of 6.2x compared to the industry average, and a discounted cash flow model suggests a much higher intrinsic value, despite risks like an anticipated net income decline. Investors are left to weigh the company's strong performance and potential upside against these risks.
Vanguard Group Inc. Sells 81,916 Shares of Innoviva, Inc. $INVA
Vanguard Group Inc. reduced its stake in Innoviva, Inc. by 1.1% in the third quarter, selling 81,916 shares but still retaining over 7 million shares valued at approximately $129.5 million. Innoviva reported strong quarterly earnings, beating revenue and EPS estimates, and holds a "Moderate Buy" consensus rating with a target price of $38.17 despite some near-term analyst revisions. Recent news includes price target increases from Cantor Fitzgerald and HC Wainwright, balanced by a Theravance Phase 3 failure and HC Wainwright's cut to 2026 EPS estimates for Innoviva.
Innoviva, Inc. $INVA Shares Bought by Royce & Associates LP
Royce & Associates LP significantly increased its stake in Innoviva, Inc. (NASDAQ:INVA) by 641.2% in the third quarter, acquiring 437,654 additional shares and bringing its total holdings to 505,906 shares. Other institutional investors also raised their positions, leading to institutional ownership of 99.12% of Innoviva's stock. The biotechnology company recently reported strong quarterly earnings, beating analyst estimates, and has an average analyst target price of $38.17, despite some near-term EPS forecast trimming.
Innoviva’s 2025 Earnings and NUZOLVENCE Launch Might Change The Case For Investing In Innoviva (INVA)
Innoviva (INVA) recently announced strong Q4 and full-year 2025 financial results, including significant revenue and net income, partly due to a one-off gain. The company's investment narrative is shifting from a royalty-focused model to a commercial portfolio in specialty therapeutics, bolstered by the U.S. FDA approval of NUZOLVENCE®. While these developments are positive, investors are urged to consider the impact of one-off gains on recent earnings and the stock's current valuation, which some analysts believe might be above fair value.
INNOVIVA INC (NASDAQ:INVA) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template
INNOVIVA INC (NASDAQ:INVA) has been identified as a high-growth momentum stock using Mark Minervini's Trend Template, which combines strict technical analysis with fundamental growth measures. The company meets key technical criteria such as trading above rising moving averages, being close to 52-week highs, and exhibiting strong relative strength. Fundamentally, Innoviva shows very high earnings growth, solid sales growth, favorable analyst estimate changes, and high profitability, making it a compelling pick for growth investors.
Innoviva’s 2025 Earnings and NUZOLVENCE Launch Might Change The Case For Investing In Innoviva (INVA)
Innoviva reported strong Q4 2025 revenue and net income, driven by its Specialty Therapeutics platform and the U.S. FDA approval of NUZOLVENCE. These results, along with an expanded share buyback, reinforce the company's shift from a royalty-focused model to a commercial portfolio in hospital-based and infectious disease treatments. However, investors are advised to consider that recent earnings relied partly on one-off gains and differing fair value estimates exist.
Innoviva, Inc. (INVA): A Bull Case Theory
This article summarizes a bullish thesis on Innoviva, Inc. (INVA), highlighting its transition from a royalty-based model to a growing commercial pharmaceutical platform, Innoviva Specialty Therapeutics (IST). The company, currently undervalued by the market, is positioned for significant upside as the IST platform expands and converts revenue into strong free cash flow, offering an asymmetric risk/reward opportunity despite execution risks.
Cantor Fitzgerald Lifts PT on Innoviva, Inc. (INVA) to $32 from $31 - Here's Why
Cantor Fitzgerald raised its price target for Innoviva, Inc. (INVA) to $32 from $31, maintaining an Overweight rating, following strong fiscal Q4 2025 results. The company's revenue surpassed expectations due to XacDuro inventory builds in China and the durable royalties portfolio, alongside a significant 47% year-over-year growth in IST product sales. Innoviva also announced the FDA approval of NUZOLVENCE® and initiated a $125 million share repurchase program.
Innoviva (INVA) One Off Gain Driven 65.9% Margin Challenges Bullish Earnings Narratives
Innoviva (INVA) concluded FY 2025 with strong Q4 revenues and EPS, but its 65.9% net profit margin was significantly boosted by a US$161.6 million one-off gain. This challenges bullish narratives, as analysts predict an earnings decline over the next three years, and the company's five-year annualized earnings have declined by 22.1%. The low P/E ratio of 6.5x, compared to an industry average of 19.9x, is seen by some as reflecting softer long-term trends and non-recurring profits.
Cantor Fitzgerald Lifts PT on Innoviva, Inc. (INVA) to $32 from $31 – Here’s Why
Cantor Fitzgerald raised its price target on Innoviva, Inc. (INVA) to $32 from $31, maintaining an Overweight rating, after the company reported strong Q4 2025 revenues that surpassed expectations. The increase was driven by XacDuro inventory builds in China, projected to boost future royalties and milestones, and the FDA approval of NUZOLVENCE®. Innoviva also initiated a $125 million share repurchase program in Q4 2025.
Innoviva (NASDAQ: INVA) 2025 net income hits $271M on higher sales
Innoviva reported substantial financial growth in 2025, with total revenue increasing to $411.3 million and net income soaring to $271.2 million, significantly up from $23.4 million in the previous year. This performance was driven by a strong royalties portfolio and a 47% year-over-year increase in U.S. net product sales from Innoviva Specialty Therapeutics, which is projected to reach at least $150 million in 2026. The company also strengthened its balance sheet, initiated a $125 million share repurchase program, and expanded its product pipeline with new FDA approvals and product launches.
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
Innoviva reported strong financial results for Q4 and full year 2025, with revenue exceeding $400 million and net income over $270 million, driven by its royalties portfolio and significant growth in Innoviva Specialty Therapeutics (IST) sales. Key achievements include the FDA approval of NUZOLVENCE® for gonorrhea, the launch of ZEVTERA, and the initiation of a $125 million share repurchase program. The company anticipates continued growth for IST, projecting $150 million or more in U.S. net product sales for 2026.
Innoviva, Inc. (INVA): A Bull Case Theory
This article summarizes a bullish thesis on Innoviva, Inc. (INVA), highlighting its transformation from a royalty-generating company to one focused on commercial operations through its Innoviva Specialty Therapeutics (IST) platform. Despite expiring royalties, the new platform's growth and strong operating leverage, combined with a solid balance sheet, present an asymmetric risk/reward opportunity for investors. The market is seen to be undervaluing the commercial platform, suggesting a fair value around $35 per share.
Innoviva CEO Details 3-Part Growth Plan, $125M Buyback, and 2026 Catalysts at Oppenheimer Conference
Innoviva CEO Pavel Raifeld outlined the company's three-part growth strategy, which includes respiratory royalties, its growing Innoviva Specialty Therapeutics (IST) commercial platform, and a portfolio of strategic healthcare investments. The company has a strong cash position of over $500 million, announced a $125 million share repurchase program, and highlighted key near-term catalysts including Armata's planned Phase III start and commercial launches for ZEVTERA and NUZOLVENCE. Despite being slow, the anti-infective launches are making progress, with ZEVTERA gaining important reimbursement designations and NUZOLVENCE preparing for a second-half 2026 launch.
Innoviva, Inc. Hits New 52-Week High at $24.25, Showcasing Strong Growth
Innoviva, Inc., a small-cap pharmaceutical and biotechnology company, has reached a new 52-week high of $24.25, marking a 52.07% increase over the past year. The company's strong performance is supported by a market capitalization of $2,497 million, a favorable P/E ratio of 14.00, and a 14.23% return on equity. Despite a conservative debt-to-equity ratio and no dividends, Innoviva Inc. continues to prioritize reinvestment for growth.
Innoviva, Inc. (NASDAQ:INVA) Receives Average Recommendation of "Moderate Buy" from Brokerages
Innoviva, Inc. (NASDAQ:INVA) has received an average recommendation of "Moderate Buy" from eight brokerages, with a consensus 1-year target price of $38.17. This follows an earnings beat, where the company reported quarterly EPS of $1.94 against an expected $0.34 and revenues of $114.61 million, significantly exceeding estimates. Institutional investors hold a substantial 99.1% of the company's stock, which currently trades with a market cap of $1.76 billion and a P/E ratio of 7.7.
Innoviva (INVA) One Off Gain Driven 65.9% Margin Challenges Bullish Earnings Narratives
Innoviva (INVA) reported strong Q4 2025 earnings with a 65.9% net profit margin and basic EPS of US$2.19, but this was significantly boosted by a US$161.6 million one-off gain. The article highlights that while recent performance shows a turnaround, the long-term earnings trend and analyst forecasts for declining earnings raise questions about the durability of these high margins and the sustainability of a bullish narrative. Innoviva's low P/E ratio compared to the industry average is also noted in contrast to its softer long-term earnings trajectory.
Cantor Fitzgerald Maintains Overweight on INVA Innoviva, Inc Feb 26 2026
Cantor Fitzgerald maintained an Overweight rating on Innoviva, Inc. (INVA) on February 26, 2026, and raised its price target to $32. This positive analyst view suggests expected outperformance for INVA compared to its peers. Despite the upgrade, the stock reacted with a -3.1% decline on the day of the announcement.
Innoviva Inc reports results for the quarter ended September 30 - Earnings Summary
Innoviva Inc has released its earnings summary for the quarter that ended on September 30, 2026. The report was provided by Refinitiv and is a concise overview for investors and analysts interested in the company's financial performance.
Innoviva’s NUZOLVENCE Approval And Buyback Reframe Growth And Valuation Story
Innoviva (NasdaqGS:INVA) has received FDA approval for NUZOLVENCE, a new treatment for uncomplicated urogenital gonorrhea, and concurrently announced a US$125 million share repurchase program. These developments indicate a strategic shift towards specialty therapeutics and a commitment to returning capital to shareholders. The stock has already seen positive momentum, and its current price is significantly below analyst targets and estimated fair value.
Innoviva's (INVA) "Buy" Rating Reiterated at BTIG Research
BTIG Research has reiterated a "Buy" rating on Innoviva (NASDAQ:INVA) with a $35 price target, indicating a potential 44% upside. This follows Innoviva's strong quarterly performance, where it exceeded EPS and revenue expectations. The company also holds a "Moderate Buy" consensus rating from other analysts, with institutional investors owning approximately 99% of its stock.
